Posiphen is undergoing clinical trials as an APP translation blocker that generates anti-amyloid efficacy [21,22,23,24] and may also cause measurable anemia and would necessitate co-treatment with iron supplements [25]. The gene discussed is APP; the disease is anemia (phenotype).